rHuEpo administration in patients with low-risk myelodysplastic syndromes: Evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples

Gian Matteo Rigolin, Matteo Della Porta, Renato Bigoni, Francesco Cavazzini, Maria Ciccone, Antonella Bardi, Antonio Cuneo, Gianluigi Castoldi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The issue of whether, in patients affected by myelodysplastic syndromes (MDS), haematological response to cytokines, particularly to recombinant human erythropoietin (rHuEpo), is a phenomenon related to the stimulation of normal haemopoietic cells or to the differentiation of cells belonging to the abnormal clone remains an open question. To assess the pattern of response to rHuEpo treatment of bone marrow (BM) cells, we evaluated in 13 low-risk MDS patients with known cytogenetic abnormalities the number of cytogenetically normal and abnormal cells by conventional cytogenetic analysis (CCA) and by a fluorescence in situ hybridization (FISH) technique, enabling the simultaneous visualization of FISH chromosomal abnormalities in morphologically and immunophenotypically identifiable BM elements. Patients responding to rHuEpo presented a lower number of abnormal metaphases at diagnosis in comparison with patients who did not respond (22.74% vs 76.23%, P = <0.001). This was confirmed by the combined morphological FISH analysis, showing that, before treatment, BM samples from patients responding to rHuEpo had a lower proportion of both FISH abnormal erythroid (36.48% vs 66.93%, P = 0.002) and myeloid (40.76% vs 67.70%, P = 0.014) elements than unresponsive patients. After rHuEpo treatment, responding patients presented a significantly lower proportion of FISH abnormal erythroid precursors than observed before treatment (16.93% vs 36.48%, P = 0.017). Likewise, in responding patients, a significantly lower proportion of FISH abnormal erythroid elements (16.93% vs 66.30%, P <0.001) was detected in comparison with unresponsive patients. These findings provide evidence that, in low-risk MDS patients with known cytogenetic abnormalities, response to rHuEpo may be due to the proliferation of karyotypically normal erythroid precursors, possibly representing residual normal erythroid elements.

Original languageEnglish
Pages (from-to)652-659
Number of pages8
JournalBritish Journal of Haematology
Volume119
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Myelodysplastic Syndromes
Erythropoietin
Fluorescence In Situ Hybridization
Bone Marrow
Chromosome Aberrations
May-Grunwald Giemsa
Cytogenetic Analysis
Therapeutics
Metaphase
Bone Marrow Cells
Cell Differentiation
Clone Cells
Cytokines

Keywords

  • FISH
  • Morphology
  • Myelodysplastic syndromes
  • Recombinant human erythropoietin

ASJC Scopus subject areas

  • Hematology

Cite this

rHuEpo administration in patients with low-risk myelodysplastic syndromes : Evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. / Rigolin, Gian Matteo; Della Porta, Matteo; Bigoni, Renato; Cavazzini, Francesco; Ciccone, Maria; Bardi, Antonella; Cuneo, Antonio; Castoldi, Gianluigi.

In: British Journal of Haematology, Vol. 119, No. 3, 2002, p. 652-659.

Research output: Contribution to journalArticle

Rigolin, Gian Matteo ; Della Porta, Matteo ; Bigoni, Renato ; Cavazzini, Francesco ; Ciccone, Maria ; Bardi, Antonella ; Cuneo, Antonio ; Castoldi, Gianluigi. / rHuEpo administration in patients with low-risk myelodysplastic syndromes : Evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. In: British Journal of Haematology. 2002 ; Vol. 119, No. 3. pp. 652-659.
@article{22b4a4fa479948c5b46e463f13b5ff7d,
title = "rHuEpo administration in patients with low-risk myelodysplastic syndromes: Evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples",
abstract = "The issue of whether, in patients affected by myelodysplastic syndromes (MDS), haematological response to cytokines, particularly to recombinant human erythropoietin (rHuEpo), is a phenomenon related to the stimulation of normal haemopoietic cells or to the differentiation of cells belonging to the abnormal clone remains an open question. To assess the pattern of response to rHuEpo treatment of bone marrow (BM) cells, we evaluated in 13 low-risk MDS patients with known cytogenetic abnormalities the number of cytogenetically normal and abnormal cells by conventional cytogenetic analysis (CCA) and by a fluorescence in situ hybridization (FISH) technique, enabling the simultaneous visualization of FISH chromosomal abnormalities in morphologically and immunophenotypically identifiable BM elements. Patients responding to rHuEpo presented a lower number of abnormal metaphases at diagnosis in comparison with patients who did not respond (22.74{\%} vs 76.23{\%}, P = <0.001). This was confirmed by the combined morphological FISH analysis, showing that, before treatment, BM samples from patients responding to rHuEpo had a lower proportion of both FISH abnormal erythroid (36.48{\%} vs 66.93{\%}, P = 0.002) and myeloid (40.76{\%} vs 67.70{\%}, P = 0.014) elements than unresponsive patients. After rHuEpo treatment, responding patients presented a significantly lower proportion of FISH abnormal erythroid precursors than observed before treatment (16.93{\%} vs 36.48{\%}, P = 0.017). Likewise, in responding patients, a significantly lower proportion of FISH abnormal erythroid elements (16.93{\%} vs 66.30{\%}, P <0.001) was detected in comparison with unresponsive patients. These findings provide evidence that, in low-risk MDS patients with known cytogenetic abnormalities, response to rHuEpo may be due to the proliferation of karyotypically normal erythroid precursors, possibly representing residual normal erythroid elements.",
keywords = "FISH, Morphology, Myelodysplastic syndromes, Recombinant human erythropoietin",
author = "Rigolin, {Gian Matteo} and {Della Porta}, Matteo and Renato Bigoni and Francesco Cavazzini and Maria Ciccone and Antonella Bardi and Antonio Cuneo and Gianluigi Castoldi",
year = "2002",
doi = "10.1046/j.1365-2141.2002.03867.x",
language = "English",
volume = "119",
pages = "652--659",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - rHuEpo administration in patients with low-risk myelodysplastic syndromes

T2 - Evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples

AU - Rigolin, Gian Matteo

AU - Della Porta, Matteo

AU - Bigoni, Renato

AU - Cavazzini, Francesco

AU - Ciccone, Maria

AU - Bardi, Antonella

AU - Cuneo, Antonio

AU - Castoldi, Gianluigi

PY - 2002

Y1 - 2002

N2 - The issue of whether, in patients affected by myelodysplastic syndromes (MDS), haematological response to cytokines, particularly to recombinant human erythropoietin (rHuEpo), is a phenomenon related to the stimulation of normal haemopoietic cells or to the differentiation of cells belonging to the abnormal clone remains an open question. To assess the pattern of response to rHuEpo treatment of bone marrow (BM) cells, we evaluated in 13 low-risk MDS patients with known cytogenetic abnormalities the number of cytogenetically normal and abnormal cells by conventional cytogenetic analysis (CCA) and by a fluorescence in situ hybridization (FISH) technique, enabling the simultaneous visualization of FISH chromosomal abnormalities in morphologically and immunophenotypically identifiable BM elements. Patients responding to rHuEpo presented a lower number of abnormal metaphases at diagnosis in comparison with patients who did not respond (22.74% vs 76.23%, P = <0.001). This was confirmed by the combined morphological FISH analysis, showing that, before treatment, BM samples from patients responding to rHuEpo had a lower proportion of both FISH abnormal erythroid (36.48% vs 66.93%, P = 0.002) and myeloid (40.76% vs 67.70%, P = 0.014) elements than unresponsive patients. After rHuEpo treatment, responding patients presented a significantly lower proportion of FISH abnormal erythroid precursors than observed before treatment (16.93% vs 36.48%, P = 0.017). Likewise, in responding patients, a significantly lower proportion of FISH abnormal erythroid elements (16.93% vs 66.30%, P <0.001) was detected in comparison with unresponsive patients. These findings provide evidence that, in low-risk MDS patients with known cytogenetic abnormalities, response to rHuEpo may be due to the proliferation of karyotypically normal erythroid precursors, possibly representing residual normal erythroid elements.

AB - The issue of whether, in patients affected by myelodysplastic syndromes (MDS), haematological response to cytokines, particularly to recombinant human erythropoietin (rHuEpo), is a phenomenon related to the stimulation of normal haemopoietic cells or to the differentiation of cells belonging to the abnormal clone remains an open question. To assess the pattern of response to rHuEpo treatment of bone marrow (BM) cells, we evaluated in 13 low-risk MDS patients with known cytogenetic abnormalities the number of cytogenetically normal and abnormal cells by conventional cytogenetic analysis (CCA) and by a fluorescence in situ hybridization (FISH) technique, enabling the simultaneous visualization of FISH chromosomal abnormalities in morphologically and immunophenotypically identifiable BM elements. Patients responding to rHuEpo presented a lower number of abnormal metaphases at diagnosis in comparison with patients who did not respond (22.74% vs 76.23%, P = <0.001). This was confirmed by the combined morphological FISH analysis, showing that, before treatment, BM samples from patients responding to rHuEpo had a lower proportion of both FISH abnormal erythroid (36.48% vs 66.93%, P = 0.002) and myeloid (40.76% vs 67.70%, P = 0.014) elements than unresponsive patients. After rHuEpo treatment, responding patients presented a significantly lower proportion of FISH abnormal erythroid precursors than observed before treatment (16.93% vs 36.48%, P = 0.017). Likewise, in responding patients, a significantly lower proportion of FISH abnormal erythroid elements (16.93% vs 66.30%, P <0.001) was detected in comparison with unresponsive patients. These findings provide evidence that, in low-risk MDS patients with known cytogenetic abnormalities, response to rHuEpo may be due to the proliferation of karyotypically normal erythroid precursors, possibly representing residual normal erythroid elements.

KW - FISH

KW - Morphology

KW - Myelodysplastic syndromes

KW - Recombinant human erythropoietin

UR - http://www.scopus.com/inward/record.url?scp=0036433664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036433664&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03867.x

DO - 10.1046/j.1365-2141.2002.03867.x

M3 - Article

C2 - 12437640

AN - SCOPUS:0036433664

VL - 119

SP - 652

EP - 659

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -